Finance

Lists
Outlook: 66.7% bullish·0.0% bearish
Go to analysis
MLYS:NASDAQ
Mineralys Therapeutics Inc
$15.52
-1.83%
(-0.29) 1D
$15.69
+1.10% (+0.17)
Pre-market
Closed: Nov 10, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLYS...
Open
$15.48
High
$16.52
Low
$15.05
Mkt. cap
1.37B
Avg. vol.
1.77M
Volume
101.00
52-wk high
$47.65
52-wk low
$14.95
EPS
-$4.36
Beta
0.83
Shares outstanding
88.56M
No. of employees
76
Open
$15.48
High
$16.52
Low
$15.05
Mkt. cap
1.37B
Avg. vol.
1.77M
Volume
101.00
52-wk high
$47.65
52-wk low
$14.95
EPS
-$4.36
Beta
0.83
Shares outstanding
88.56M
No. of employees
76
News stories
From web sources and news partners
About Mineralys Therapeutics Inc
CEO-
Employees76
Founded2019
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitemineralystx.com
Analyst ratings
Based on 9 analysts giving stock ratings to MLYS in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for MLYS in the last 3 months.
Highest
Current $15.52
$56.00 (+260.82%)
Average
$46.86 (+201.93%)
Lowest
$19.00 (+22.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$56.00
+260.8%
11/10/2026
Alice Nettleton
UBS
Hold
Reiterated
$19.00
+22.4%
11/06/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$55.00
+254.4%
11/05/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
11/05/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$52.00
+235.1%
11/05/2026
Unknown Analyst
UBS
Hold
Initiated
$29.00
+86.9%
10/11/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$52.00
+235.1%
08/12/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$40.00
+157.7%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$55.00
+254.4%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$54.00
+247.9%
08/12/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$42.00
+170.6%
05/07/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
-$0.64 / -$0.55
-15.91%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24.40M
24.36M
221.38M
22.67M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.88M
20.98M
24.66M
37.42M
Operating expense
38.28M
45.34M
246.04M
60.09M
Total operating expenses
38.28M
45.34M
246.04M
60.09M
Operating income
-38.28M
-45.34M
-246.04M
-60.09M
Other non operating income
1.00K
5.00K
13.00K
-
EBT including unusual items
-32.23M
-39.34M
-241.07M
-57.33M
EBT excluding unusual items
-32.23M
-39.34M
-241.07M
-57.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32.23M
-39.34M
-241.07M
-57.33M
Net profit margin
-
-
-
-
Earnings per share
-0.40
-0.47
-2.85
-0.64
Interest and investment income
6.04M
6.00M
4.96M
5.95M
Interest expense
-
-
-
-3.19M
Net interest expenses
6.04M
6.00M
4.96M
2.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-38.27M
-45.33M
-246.04M
-60.08M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps